Therapeutic approaches to chronic hyperuricemia and gout.

Item

http://www.wikidata.org/entity/Q38201666

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Therapeutic approaches to chronic hyperuricemia and gout.

@en

type

Item

label

Therapeutic approaches to chronic hyperuricemia and gout.

@en

prefLabel

Therapeutic approaches to chronic hyperuricemia and gout.

@en

P1476

Therapeutic approaches to chronic hyperuricemia and gout.

@en

P2093

Raffaella Bocale

http://www.w3.org/2001/XMLSchema#string

Roberto Pontremoli

http://www.w3.org/2001/XMLSchema#string

P2860

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition

Uric acid transport and disease

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study.

P2888

s40292-014-0051-6

P304

243-250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40292-014-0051-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Davide Grassi

Claudio Ferri

Giovambattista Desideri

P577

2014-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261328086

http://www.w3.org/2001/XMLSchema#string

P698

24696068

http://www.w3.org/2001/XMLSchema#string